Passage Bio to Participate in H.C. Wainwright 27th Annual Global Investment Conference

Rhea-AI Summary

Passage Bio (NASDAQ: PASG), a clinical-stage genetic medicines company specializing in neurodegenerative diseases, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York City.

CEO Will Chou, M.D., will deliver a company overview presentation and the management team will engage in one-on-one investor meetings. The presentation will be available via video webcast to conference attendees starting September 5, 2025, at 7:00 a.m. ET, with a 30-day replay period accessible through the company's investor relations website.

News Market Reaction – PASG

-1.99%

1 alert

-1.99% Session close to close

$22.66M Market Cap

0.7x Rel. Volume

In the Aug 28 session, PASG declined 1.99%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PHILADELPHIA, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that management will participate in the H.C. Wainwright 27th Annual Global Investment Conference being held from September 8-10, 2025 in New York City.

Will Chou, M.D., president and chief executive officer, will present an overview of the company, and management will participate in one-on-one meetings with investors. A video webcast of the presentation will be available to registered conference attendees via the conference platform beginning Friday, September 5, 2025, at 7:00 a.m. ET and will be available on the Investors & News section of Passage Bio’s website at investors.passagebio.com. A replay of the presentation will be available for 30 days following the event.

About Passage Bio

Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases. Our primary focus is the development and advancement of cutting-edge, one-time therapies designed to target the underlying pathology of these conditions. Passage Bio’s lead product candidate, PBFT02, seeks to treat neurodegenerative conditions, including frontotemporal dementia, by elevating progranulin levels to restore lysosomal function and slow disease progression.

To learn more about Passage Bio and our steadfast commitment to protecting patients and families against loss in neurodegenerative conditions, please visit: passagebio.com.

For further information, please contact:

Investors:
Stuart Henderson
Passage Bio
shenderson@passagebio.com

Passage Bio Media:
Mike Beyer
Sam Brown Inc. Healthcare Communications
312.961.2502
mikebeyer@sambrown.com

FAQ

When is Passage Bio presenting at the H.C. Wainwright Conference 2025?

The presentation will be available via webcast starting September 5, 2025, at 7:00 a.m. ET, with the conference running from September 8-10, 2025 in New York City.

Who will be presenting for Passage Bio (PASG) at the H.C. Wainwright Conference?

Will Chou, M.D., president and chief executive officer of Passage Bio, will present the company overview.

How can investors access Passage Bio's H.C. Wainwright Conference presentation?

The video webcast will be available to registered conference attendees via the conference platform and on Passage Bio's website at investors.passagebio.com for 30 days after the event.

What is Passage Bio's (PASG) main business focus?

Passage Bio is a clinical-stage genetic medicines company focused on developing treatments for patients with neurodegenerative diseases.